# Intarcia Therapeutics cuts 60 employees after FDA rejection

Privately-held Intarcia Therapeutics cut 60 employees and received a clinical hold for two marketing studies, four months after the FDA rejected its diabetes drug-eluting implant.

- Type: Closure
- Announced: 2018-02-05
- Where: United States
- Jobs: -60
- Status: completed
- Products: diabetes drug-eluting implant
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Intarcia Therapeutics](https://endata.com/companies/29848.md)

## Sources

- [massdevice.com](https://www.massdevice.com/massdevice-article-archive/page/1761/), 2018-02-05: "Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies, according to reports."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.